Equity research analysts from prominent international financial institutions and healthcare investment banks—including firms such as Piper Sandler, Canaccord Genuity, and KBC Securities—actively cover Nyxoah (NASDAQ / Euronext: NYXH). These life science specialists publish regular research reports, valuation models, and 12-month price targets evaluating the company's clinical trial milestones, regulatory approvals, and commercial expansion metrics for institutional and retail investors.